These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39139778)

  • 81. Predictors of availability of long-acting medication for opioid use disorder.
    Shover CL; Humphreys K
    Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Evaluation of a Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk.
    Naumann RB; Roberts AW; Marshall SW; Skinner AC
    Med Care; 2019 Mar; 57(3):213-217. PubMed ID: 30629016
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder.
    Andraka-Christou B; Nguyen T; Bradford DW; Simon K
    J Subst Abuse Treat; 2020 Mar; 110():49-58. PubMed ID: 31952628
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: A retrospective case-control study.
    Smolina K; Crabtree A; Chong M; Park M; Mill C; Zhao B; Schütz CG
    Subst Abus; 2022; 43(1):92-98. PubMed ID: 32441588
    [No Abstract]   [Full Text] [Related]  

  • 86. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults.
    Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD
    J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study.
    Morse E; Binswanger IA; Taylor E; Gray C; Stimmel M; Timko C; Harris AHS; Smelson D; Finlay AK
    J Subst Abuse Treat; 2021 Oct; 129():108353. PubMed ID: 34080564
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System.
    Abraham AJ; Yarbrough CR; Harris SJ; Adams GB; Andrews CM
    Psychiatr Serv; 2021 Feb; 72(2):148-155. PubMed ID: 33267651
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain.
    Chapman SA; Fraimow-Wong L; Phoenix BJ; Tierney M; Spetz J
    J Subst Use Addict Treat; 2024 Feb; 157():209215. PubMed ID: 37979946
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Estimating the impact of insurance expansion on colorectal cancer and related costs in North Carolina: A population-level simulation analysis.
    Hassmiller Lich K; O'Leary MC; Nambiar S; Townsley RM; Mayorga ME; Hicklin K; Frerichs L; Shafer PR; Davis MM; Wheeler SB
    Prev Med; 2019 Dec; 129S():105847. PubMed ID: 31666187
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
    Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
    [No Abstract]   [Full Text] [Related]  

  • 92. Impacts of a Medicaid "lock-in" program on opioid use disorder treatment and services and naloxone dispensing.
    Naumann RB; Austin AE; Wang L; Roberts AW
    Drug Alcohol Depend; 2022 Apr; 233():109385. PubMed ID: 35276627
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The impact of the opioid crisis on U.S. state prison systems.
    Scott CK; Dennis ML; Grella CE; Mischel AF; Carnevale J
    Health Justice; 2021 Jul; 9(1):17. PubMed ID: 34304335
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
    Curran L; Manuel J
    Int J Drug Policy; 2024 Apr; 126():104342. PubMed ID: 38479161
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs.
    Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M
    Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
    Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Simulating the effects of medicaid expansion on the opioid epidemic in North Carolina.
    Berghammer A; Adams JW; Khan S; Bobashev G
    Drug Alcohol Depend Rep; 2024 Sep; 12():100262. PubMed ID: 39139778
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.
    Savinkina A; Madushani RWMA; Eftekhari Yazdi G; Wang J; Barocas JA; Morgan JR; Assoumou SA; Walley AY; Linas BP; Murphy SM
    Addiction; 2022 Sep; 117(9):2450-2461. PubMed ID: 35315162
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.